EA201691218A1 - Агонисты a1-аденозиновых рецепторов в качестве лекарственного средства для лечения заболеваний почек - Google Patents

Агонисты a1-аденозиновых рецепторов в качестве лекарственного средства для лечения заболеваний почек

Info

Publication number
EA201691218A1
EA201691218A1 EA201691218A EA201691218A EA201691218A1 EA 201691218 A1 EA201691218 A1 EA 201691218A1 EA 201691218 A EA201691218 A EA 201691218A EA 201691218 A EA201691218 A EA 201691218A EA 201691218 A1 EA201691218 A1 EA 201691218A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
medicine
agonists
kidney diseases
adenosine receptors
Prior art date
Application number
EA201691218A
Other languages
English (en)
Inventor
Барбара Альбрехт-Кюппер
Кирстен Лайневебер
Аксель Кретшмер
Даниель Майбом
Александрос Вакалопулос
Николь Дидрихс
Катя Циммерманн
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49759125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691218(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201691218A1 publication Critical patent/EA201691218A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение касается селективных парциальных агонистов А1-аденозиновых рецепторов формулы (I) и их применения для лечения и/или профилактики заболеваний, а также их применения для получения лекарственного средства для лечения и/или профилактики заболеваний, предпочтительно для лечения и/или профилактики острых и/или хронических заболеваний почек (первичного заболевания и вторичного заболевания) с и без сопровождающих острых и/или хронических сердечных заболеваний.
EA201691218A 2013-12-12 2014-12-09 Агонисты a1-аденозиновых рецепторов в качестве лекарственного средства для лечения заболеваний почек EA201691218A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13196780 2013-12-12
PCT/EP2014/076978 WO2015086561A1 (de) 2013-12-12 2014-12-09 Adenosin a1 agonisten als arzneimittel gegen nierenerkrankungen

Publications (1)

Publication Number Publication Date
EA201691218A1 true EA201691218A1 (ru) 2016-11-30

Family

ID=49759125

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691218A EA201691218A1 (ru) 2013-12-12 2014-12-09 Агонисты a1-аденозиновых рецепторов в качестве лекарственного средства для лечения заболеваний почек

Country Status (21)

Country Link
US (1) US20160311812A1 (ru)
EP (1) EP3079696A1 (ru)
JP (1) JP2016539986A (ru)
KR (1) KR20160094974A (ru)
CN (1) CN105792826A (ru)
AP (1) AP2016009245A0 (ru)
AU (1) AU2014363705A1 (ru)
CA (1) CA2933244A1 (ru)
CL (1) CL2016001357A1 (ru)
EA (1) EA201691218A1 (ru)
IL (1) IL245866A0 (ru)
MA (1) MA39101A1 (ru)
MX (1) MX2016007343A (ru)
MY (1) MY174230A (ru)
PH (1) PH12016501127A1 (ru)
SG (1) SG11201604414PA (ru)
SV (1) SV2016005210A (ru)
TN (1) TN2016000233A1 (ru)
UA (1) UA117771C2 (ru)
WO (1) WO2015086561A1 (ru)
ZA (1) ZA201603465B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7055429B2 (ja) * 2017-10-27 2022-04-18 学校法人北里研究所 慢性腎臓病の予防又は治療剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE102007036075A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Ag Prodrugs und ihre Verwendung
DE102007036076A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension

Also Published As

Publication number Publication date
MA39101A1 (fr) 2017-08-31
PH12016501127A1 (en) 2016-07-18
MY174230A (en) 2020-04-01
EP3079696A1 (de) 2016-10-19
JP2016539986A (ja) 2016-12-22
KR20160094974A (ko) 2016-08-10
CL2016001357A1 (es) 2017-01-13
SV2016005210A (es) 2017-08-08
UA117771C2 (uk) 2018-09-25
AP2016009245A0 (en) 2016-05-31
CN105792826A (zh) 2016-07-20
MX2016007343A (es) 2016-09-13
AU2014363705A1 (en) 2016-06-30
CA2933244A1 (en) 2015-06-18
TN2016000233A1 (en) 2017-10-06
ZA201603465B (en) 2019-07-31
US20160311812A1 (en) 2016-10-27
WO2015086561A1 (de) 2015-06-18
IL245866A0 (en) 2016-07-31
SG11201604414PA (en) 2016-07-28

Similar Documents

Publication Publication Date Title
EA201501142A1 (ru) Гетероциклические соединения в качестве средств для борьбы с вредителями
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
EA201690268A1 (ru) Замещенные производные хиназолин-4-она
EA201591087A1 (ru) Новые производные бензимидазола в качестве антагонистов рецептора ep4
EA201591244A1 (ru) Противовирусные соединения
EA201790963A1 (ru) Противовирусные соединения
EA201790781A2 (ru) Противовирусные соединения
EA201790785A1 (ru) Производные тетрагидроизохинолина
EA201692001A1 (ru) Способ получения amg 416
EA201590520A1 (ru) Фармацевтическая композиция с покрытием, содержащая регорафениб
EA201400567A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201491854A1 (ru) Асимметрический синтез соединений спирооксиндола, полезных в качестве терапевтических средств
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
EA201500651A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛ- И ХИНУКЛИДИНИЛКАРБАМАТА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
BR112015020199A2 (pt) usos terapêuticos para anticorpos de vegfr1
EA201600288A1 (ru) Замещенные фенилаланиновые производные
EA201501187A1 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
EA201491651A1 (ru) Новые соединения для лечения дислипидемии и родственных заболеваний
PH12016500042A1 (en) Stabilized pharmaceutical dosage forms comprising atrasentan
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов